Investor Relations
Join the revolution in radiation-free diagnostics. Three investment rounds. One transformative opportunity. Be part of scaling REMS technology across the US and beyond.
By the Numbers
3,000+
Scans
4.95
Rating
6
Locations
60+
US REMS
37K+
Visitors
$325
Per Scan
Traction
3,000+
Scans Completed
4.95/5
Client Satisfaction
6
Active Locations
37K+
Monthly Visitors
$950K
Y1 Revenue Target
Founded BioX Unlimited LLC
First REMS device operational
Opened Strength Lab Plus studio, Naples
Partnerships with clinics, centers & companies. 6 permanent locations across FL & CA
Angel Round opens — blind crowdfunding
Round II — Exclusive investment pool
IPO target
Investment Structure
Our structured investment approach rewards early believers and builds toward a transformative exit.
Round 1
Blind Crowdfunding / SAFE
Who: Open to everyone — accredited and non-accredited investors worldwide
Earliest entry at lowest valuation. 20% discount on next round. Exclusive access to Round 2. Your percentage is determined by total pool at close.
Round 2
Exclusive Investment Pool
Who: Exclusive to Round 1 investors — proportional to initial contribution
8% annual cumulative dividends. Preferred stock with liquidation preference. Pro-rata rights.
Round 3
Institutional Round
Who: VC funds, family offices, angel groups, and accredited individual investors
Board representation potential. Anti-dilution protection. Clear path to IPO.
The Problem
of at-risk patients are never screened for bone density issues
the current standard, uses ionizing radiation and measures only density — missing bone quality entirely
average wait time for results with traditional screening methods
Our Solution
REMS uses ultrasound-based technology — completely radiation-free, safe for repeat assessments.
Measures bone density, quality, fragility score, and 5-year fracture risk — all in one 15-minute scan.
Clients walk away with results the same day. No waiting weeks for a report.
Franchise-ready "Uber for bone health" — asset-light expansion through partner network.
Competitive Landscape
Function Bone Health is the only platform combining radiation-free REMS scanning with a full consumer wellness ecosystem — marketplace, provider network, and annual monitoring.
FBH Advantages
No other competitor offers all these capabilities in a single platform.
Business Model
A multi-layered revenue model combining direct scans, provider fees, marketplace, education, annual monitoring, and future telemedicine — driving $950K Year 1 to $12M by Year 5.
$325 per REMS scan across FBH-owned locations. 3 locations in Y1 scaling to 12 by Y5 at 15-20 scans/day capacity.
Year 1
$700K
Year 5
$5.5M
15-30% commission on scans at partner REMS locations. 60+ US providers, targeting 40+ by Y5. Asset-light scaling.
Year 1
$100K
Year 5
$2.5M
Curated supplements, wellness products, and health services. 8-20% commission per sale via Stripe Connect.
Year 1
$30K
Year 5
$950K
Expert consultations ($275), wellness plans, HTMA testing, and tiered education subscriptions ($9.99–$24.99/mo).
Year 1
$20K
Year 5
$450K
Recurring $575–$799/year monitoring subscriptions with repeat scans and progress tracking. Strong retention.
Year 1
$100K
Year 5
$2.0M
$99-$199 per consultation. Concierge health plans $2,500-$5,000/year. Launching Phase 2 (2027).
Year 1
Phase 2
Year 5
$600K
Combined Platform Revenue (projected)
$950K
Year 1
$12.0M
Year 5
The Opportunity
54 million Americans have low bone density. 80% of at-risk patients are never screened. The bone health diagnostics market is ripe for disruption with radiation-free technology.
TAM
$15B+
Global osteoporosis diagnostics and bone health assessment market
SAM
$3.2B
US bone density testing and preventive screening market
SOM
$180M
Addressable market with REMS technology in first 5 years
Global Opportunity
An estimated 500-700+ REMS devices are installed globally. Every one is a potential partner on the FBH platform.
Estimated Devices
40+ target partnerships — primary market with strong regulatory alignment
Estimated Devices
Echolight HQ (Italy) + UK, Germany, France, Spain — largest installed base globally
Estimated Devices
Japan, South Korea, Australia, India — fast-growing adoption of radiation-free diagnostics
Estimated Devices
UAE, Saudi Arabia — premium wellness market with high disposable income
Estimated Devices
Brazil, Mexico — emerging market with growing health infrastructure
500-700+
Devices Worldwide
FBH's software platform (booking, marketplace, monitoring, analytics) can serve any REMS provider worldwide — turning hardware competitors into platform customers.
Unit Economics
Industry-leading customer economics powered by organic acquisition, a waitlist-to-scan engine, and high lifetime value from multi-product engagement.
CAC
$35
Customer acquisition cost via digital channels + waitlist engine
LTV
$1,850
Lifetime value (scan + add-ons + annual monitoring + marketplace)
LTV:CAC
53:1
Industry-leading ratio driven by low-cost organic acquisition
Churn
<8%
Annual plan churn rate — strong retention from ongoing monitoring value
Payback
<1 mo
Customer acquisition cost recovered on first scan visit
Gross Margin
~70%
High-margin service model with minimal COGS per scan
Our proprietary acquisition model converts local demand into booked scans. Clients join a $25 waitlist in their area. When 45 people sign up, we trigger a pop-up scanning event. 80% convert from waitlist to scan, and 15% upgrade to annual monitoring plans.
80%
Waitlist → Scan
15%
Scan → Annual
Investment Calculator
Three scenarios based on compound annual growth rate (CAGR). Hover over the chart to see exact values for each year. Round 1 (Angel/SAFE) does not include dividends.
SAFE (Simple Agreement for Future Equity) • 2026 — 2028 (2 years)
$37K
$48K
$73K
Note how sharply the curves diverge — this illustrates the inherent uncertainty and range of outcomes in early-stage investing.
| Year | Pessimistic (8%) | Average (14%) | Optimistic (24%) |
|---|---|---|---|
| Today | $25,000 | $25,000 | $25,000 |
| Year 1 | $27,000 | $28,500 | $31,000 |
| Year 2 | $29,160 | $32,490 | $38,440 |
| Year 3 | $31,493 | $37,039 | $47,666 |
| Year 4 | $34,012 | $42,224 | $59,105 |
| Year 5 | $36,733 | $48,135 | $73,291 |
| Profit | +$11,733 | +$23,135 | +$48,291 |
Methodology & Assumptions
These projections are illustrative estimates only based on compound annual growth rate modeling. They do not guarantee future performance. Actual results may vary materially. Early-stage investing carries substantial risk including total loss of investment. See Investment Disclaimer for full risk disclosures.
Use of Funds
Every dollar is allocated to accelerate growth, expand our technology platform, and bring REMS bone health scanning to more communities.
Location Expansion
New markets, REMS equipment procurement, facility setup, and geographic expansion across the United States and internationally.
Technology & Platform
Provider ecosystem, client dashboard, AI-powered analytics, and mobile app development.
Marketing & Acquisition
Brand awareness campaigns, digital marketing, SEO, partnerships, and client acquisition funnels.
Team & Operations
Key hires in operations, clinical staff, customer success, and management infrastructure.
Legal & Reserve
SEC compliance, legal counsel, insurance, licensing, and operational reserve fund.
Team
A lean, focused team combining health-tech vision, medical compliance expertise, and AI-powered engineering to scale REMS diagnostics nationally.
Founder & Ideologist
Visionary behind Function Bone Health. Conceived the REMS-first approach and drives the company's mission to make radiation-free bone health accessible to all.
CEO & Medical Compliance
Medical professional overseeing clinical compliance, provider network standards, and FDA regulatory alignment for REMS technology deployment.
Engineering & Product
AI-powered development pipeline building the platform — booking, dashboards, marketplace, provider ecosystem, and analytics. Fast iteration, zero technical debt.
Legal
Please review the following disclosures carefully before considering any investment.
This page contains forward-looking statements about the expected future performance of Function Bone Health, Inc. These statements are based on current expectations and assumptions and involve risks and uncertainties. Actual results may differ materially from those projected. Revenue projections, growth estimates, and return calculations are illustrative only and do not guarantee future performance.
Investing in early-stage companies involves substantial risk, including the potential loss of your entire investment. Key risks include but are not limited to: limited operating history, dependence on key personnel, regulatory changes affecting medical device and wellness industries, competition from established diagnostic providers, market adoption uncertainty for REMS technology, and general economic conditions. Investors should only invest amounts they can afford to lose entirely.
The information on this page is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. Any offering of securities will be made only through official offering documents filed with or exempt from registration under applicable securities laws. No money or other consideration is being solicited through this page.
A SAFE (Simple Agreement for Future Equity) is not equity and does not represent current ownership in the company. SAFEs convert to equity at a future priced funding round, subject to the terms of the SAFE agreement including valuation cap and discount rate. There is no guarantee that a conversion event will occur. SAFEs have no maturity date, bear no interest, and carry no voting rights.
Any securities offering by Function Bone Health, Inc. will comply with applicable federal and state securities laws, including but not limited to Regulation Crowdfunding (Reg CF), Regulation D Rule 506(b), and Rule 506(c) of the Securities Act of 1933. Certain investment opportunities may be limited to accredited investors as defined by SEC Rule 501.
Dividend projections shown on this page are illustrative estimates based on hypothetical future performance. Actual dividend payments, if any, will depend on the company achieving profitability, board of directors approval, and available cash flow. The company is under no obligation to pay dividends. Past performance does not guarantee future results.
Investor FAQ
A SAFE (Simple Agreement for Future Equity) is the most common instrument for early-stage investing. When you invest via a SAFE, you are not purchasing equity immediately. Instead, your investment converts to equity at the next priced funding round, typically at a discount (20%) to the price paid by later investors, subject to a valuation cap. This means early investors get more shares per dollar invested.
In Round 1, we open a 2-year investment window (2026-2028). Investors contribute at any time during this period. When the round closes, each investor's percentage is determined by their contribution relative to the total pool. For example, if the total pool raises $2M and you invested $100K, you hold 5% of the angel allocation. The larger your contribution, the greater your stake.
Your ownership percentage in Round 1 equals your investment divided by the total angel pool at close of the 2-year window. This percentage then determines your proportional allocation in Round 2 and your equity stake when the SAFE converts. The 20% SAFE discount at conversion means you effectively receive equity at a 20% lower valuation than Round 2 investors.
Dividends are applicable only to Rounds 2 and 3, where investors receive preferred stock with cumulative dividend rights (8% for Round 2, 6% for Round 3). Round 1 (Angel/SAFE) does not include dividend rights. Dividends accrue annually and are paid when the company is profitable and the board approves distributions.
At IPO (targeted for 2030), all preferred stock converts to common stock on a 1:1 basis. Investors can then sell shares on the public market. Early investors benefit from having entered at significantly lower valuations. SAFE holders from Round 1 convert at the most favorable of their discount rate or valuation cap.
Securities purchased in early-stage rounds are generally illiquid. Under Regulation Crowdfunding, SAFE securities are subject to a one-year holding period before they can be transferred, with limited exceptions. There is currently no secondary market for FBH shares. Investors should be prepared to hold their investment for an extended period (typically 5-10 years).
Round 2 is exclusively available to investors who participated in Round 1 (Angel Round). Your allocation in Round 2 is proportional to your Round 1 contribution percentage. For example, if your Round 1 investment represented 5% of the total angel pool, you have the right to invest up to 5% of the Round 2 target raise.
Round 1 (Angel): $5,000 minimum. Round 2 (Seed): $10,000 minimum. Round 3 (Series A): $50,000 minimum. Non-accredited investors in Round 1 are subject to annual investment limits under Regulation Crowdfunding based on their income and net worth.
The calculator shows three scenarios: Pessimistic (8% CAGR), Average (14% CAGR), and Optimistic (24% CAGR). For context, the S&P 500 averages ~10% annually, while strong health-tech companies can achieve 15-25%+ growth. The scenarios diverge significantly over 5 years — this illustrates the inherent uncertainty in early-stage investing. Only invest what you can afford to lose.
Join the Future
Join our angel round and become part of the REMS revolution. Early investors receive the most favorable terms and exclusive access to future rounds.
